Results 1 to 10 of about 2,814 (132)

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review [PDF]

Health Science Reports
Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety
Md. Mahmudul Islam, Md. Zahid Hasan, Md. Touki Tahamid Tusar, Md. Yeamin Hossain, Md. Motaher Hossain, Md. Abdulla Al Jubayed, Md. Jubaer‐Al‐Abedin, Sheikh Soikot, Shanzida Akther, Jahid Bhuyian, Hafizur Rahman Gazi, B. M. Mahmudul Hasan, Md. Shofiul Azam, Md. Enamul Haque, Abdullah‐Al‐Jubayer, Md. Faruk Hasan, F. M. Ali Haydar, Md. Khalekuzzaman, Md. Torequl Islam, Sohel Hasan   +19 more
doaj   +3 more sources

Delamanid-containing regimens over 24 weeks for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis: preliminary results from a single center in a multicenter, prospective, observational study [PDF]

Frontiers in Medicine
BackgroundSingle center preliminary results from a multicenter, prospective, observational study whose aims were to investigate the efficacy and safety of 24-week delamanid-containing regimens in Chinese multidrug-resistant/rifampicin-resistant ...
Fuping Yang, Mingdan Yin, Xingmei Jiang, Xing Zhao, Xuemei An, Yan Liu, Yijia Yuan   +6 more
doaj   +2 more sources

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study

Journal of Microbiology, Immunology and Infection, 2023
Background/Purpose(s): Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the ...
Ju Hwan Kim, In-Sun Oh, Han Eol Jeong
exaly   +3 more sources

A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial [PDF]

Signal Transduction and Targeted Therapy
Tuberculosis (TB) is a contagious disease that threatens human health worldwide. Combination chemotherapy is usually recommended for this disease. Recently, 2 nitroimidazole-based agents, namely, delamanid and pretomanid, have been approved by regulatory
Naihui Chu, Wenjuan Nie, Juan Du, Manni Wang, Liping Ma, Qingfeng Wang, Jun Wang, Xiaomeng Hu, Jin Wu, Yu Lu, Mailing Huang, Yuquan Wei, Zhenling Wang, Jian-Qing He, Zhenyu Ding, Xiawei Wei   +15 more
doaj   +2 more sources

Safety and outcome of bedaquiline and delamanid-based longer oral regimen in Indian children less than 5 years with drug-resistant tuberculosis [PDF]

Lung India
Background: Paediatric drug-resistant tuberculosis (DR-TB) remains a significant challenge, especially in high-burden countries like India. While bedaquiline (BDQ) and delamanid (DLM) are shown to be successful in treating multi-drug-resistant TB (MDR-TB)
Ira Shah, Ramsha Ansari, Dhruv N. Gandhi, Suhani Jain, Varsha Puri, Daksha Shah, Sanjay K. Mattoo, Minnie Bodhanwala   +7 more
doaj   +2 more sources

The role of delamanid in the treatment of drug-resistant tuberculosis

Therapeutics and Clinical Risk Management, 2015
Joseph M Lewis,1 Derek J Sloan2,3 1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK ...
Derek J Sloan, Joseph M Lewis
exaly   +2 more sources

Delamanid: Safety and Efficacy Analysis

Туберкулез и болезни лёгких, 2023
The review presents the analysis of 50 publications describing treatment of multiple drug resistant tuberculosis with regimens containing the new drug of delamanid.
G. N. Mozhokina, A. G. Samoylova, I. A. Vasilyeva, A. V. Abramchenko   +3 more
doaj   +1 more source

Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects

Туберкулез и болезни лёгких, 2021
The review analyses 61 publications on the use of delamanid, a new drug for the treatment of drug resistant tuberculosis. It presents information about pharmacokinetic parameters, efficacy and safety, as well as the place of delamanid in the combination ...
V. N. Zimina, I. B. Viktorova
doaj   +1 more source

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China

Journal of Global Antimicrobial Resistance, 2021
: Objectives: The new antituberculous drugs delamanid and bedaquiline form the last line of defence against drug-resistant tuberculosis (TB). Understanding the background prevalence of resistance to new drugs can help predict the lifetime of these drugs’
Wencong He, Chunfa Liu, Dongxin Liu, Aijing Ma, Yimeng Song, Ping He, Jingjing Bao, Yuanchun Li, Bing Zhao, Jiale Fan, Qian Cheng, Yanlin Zhao   +11 more
doaj   +1 more source

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.

PLOS Global Public Health, 2023
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results.
Carly A Rodriguez, Sara Lodi, C Robert Horsburgh, Carole D Mitnick, Mathieu Bastard, Helena Huerga, Uzma Khan, Michael Rich, Kwonjune J Seung, Sidney Atwood, Md Manzur-Ul-Alam, Nara Melikyan, Stephanie Mpinda, Zaw Myint, Yugandran Naidoo, Ofelya Petrosyan, Naseem Salahuddin, Samreen Sarfaraz, Stalz Charles Vilbrun, Kalkidan Yae, Jay Achar, Saman Ahmed, Elena Algozhina, Jude Beauchamp, Sara de Guadelupe Perea Moreno, Munara Gulanbaeva, Marika Gergedava, Cut Yulia Indah Sari, Catherine Hewison, Palwasha Khan, Molly F Franke   +30 more
doaj   +1 more source